Results of phase III trials of two approved drugs for hereditary angioedema (HAE) and another in the late-stage pipeline have finally emerged from the gauntlet of peer review. Reports on a pasteurized and nanofiltered form of human C1 esterase inhibitor (Cinryze) and the synthetic agents ecallantide (Kalbitor) and icatibant (Firazyr) -- the latter still in development -- appeared in the Aug. 4 issue of the New England Journal of Medicine.
